Related Experiment Video
Updated: Aug 6, 2025

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
Published on: June 16, 2020
[What's new in the management of systemic sclerosis]
Mona Khelifa1, Romain Guemara1, Michele Iudici1
1Service de rhumatologie, Département de médecine, Hôpitaux universitaires de Genève, 1211 Genève 14.
Abstract:
This review of the literature highlights the results of the recent randomized controlled trials about the management of systemic sclerosis (SSc) and its complications. The latest randomized studies have failed to demonstrate the utility against placebo of the injections of botulinum toxin A to achieve a better control of Raynaud's phenomenon and the efficacy of the adipose-derived cell transplantation for the treatment of hand dysfunction. Rituximab allows a significant improvement of cutaneous induration. The injections of mesenchymal stromal cells are well tolerated and should encourage future randomized trials to evaluate their efficacy. Finally, nintedanib and tocilizumab allow a reduction in the rate of decline of lung function, as well as a possible stabilization with tocilizumab.
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Atherosclerosis III: Management
Cystic Fibrosis: Management
Sinus disease and chronic...
Nephrotic Syndrome II : Assessment and Medical Management
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Nephrotic Syndrome III : Nursing Management

